Immunic, Inc. (IMUX) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Immunic, Inc.
Address
1200 Avenue of the Americas
New York City, NY 10036
United States of America (the)
Phone
332 255 9818
Website
Sector
Healthcare
Industry
Biotechnology
Employees
95
First IPO Date
April 17, 2014
Key Executives
| Name | Title | Pay | Year Born |
| Erik Lundgren | Chief Executive Officer & Director | 1.13M | 1978 |
| Glenn Whaley | Chief Financial Officer | 682,250 | 1968 |
| Jason Tardio | Chief Operating Officer & President | 751,700 | 1977 |
| Michael A. Panzara | Chief Medical Officer | 809,825 | 1967 |
| Daniel Vitt | Co-Founder & Director | 1.13M | 1968 |
| Hella Kohlhof | Co-Founder & Chief Scientific Officer | 0 | 1973 |
| Jessica Breu | Vice President of Investor Relations & Communications | 0 | N/A |
| Patrick Walsh | Chief Business Officer | 0 | 1983 |
| Inderpal Singh | General Counsel | 0 | 1966 |
| Werner Gladdines | Chief Development Officer | 0 | 1979 |
Description
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
